Evidence map›Paper›PMID 37725525›Full record

ArticleImmunology and cell biology

Broad spectrum SARS-CoV-2-specific immunity in hospitalized First Nations peoples recovering from COVID-19.

Wuji Zhang, E Bridie Clemens, Lukasz Kedzierski, Brendon Y Chua, Mark Mayo, Claire Lonzi, Alexandra Hinchcliff, Vanessa Rigas, Bianca F Middleton, Paula Binks and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunology and cell biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Wuji ZhangDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.ORCID 0000-0001-7460-4956
E Bridie ClemensDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
Lukasz KedzierskiDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
Brendon Y ChuaDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
Mark MayoMenzies School of Health Research, Darwin, NT, Australia.
Claire LonziMenzies School of Health Research, Darwin, NT, Australia.
Alexandra HinchcliffMenzies School of Health Research, Darwin, NT, Australia.
Vanessa RigasMenzies School of Health Research, Darwin, NT, Australia.
Bianca F MiddletonMenzies School of Health Research, Darwin, NT, Australia.
Paula BinksMenzies School of Health Research, Darwin, NT, Australia.ORCID 0000-0003-4844-9408
Louise C RowntreeDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
Lilith F AllenDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
Hyon-Xhi TanDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
Jan PetersenInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.ORCID 0000-0002-2045-6342
Priyanka ChaurasiaInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA.
Adam K WheatleyDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
Stephen J KentDepartment of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.ORCID 0000-0002-8539-4891
Jamie RossjohnInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
Adrian MillerIndigenous Engagement, CQ University, Townsville, QLD, Australia.
Sarah LynarMenzies School of Health Research, Darwin, NT, Australia.
Jane NelsonMenzies School of Health Research, Darwin, NT, Australia.
Thi Ho Nguyen *Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.ORCID 0000-0002-9294-7693
Jane Davies *Menzies School of Health Research, Darwin, NT, Australia.
Katherine Kedzierska *Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.ORCID 0000-0001-6141-335X

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00018 · NIAID · UNIVERSITY OF GEORGIA · PI TOMPKINS, S. MARK · 2021 to 2025
$21.6M
NIAID NIH HHS 75N93021C00018NIH HHS 75N93021C00018
6 · The paper itself

Abstract

Indigenous peoples globally are at increased risk of COVID-19-associated morbidity and mortality. However, data that describe immune responses to SARS-CoV-2 infection in Indigenous populations are lacking. We evaluated immune responses in Australian First Nations peoples hospitalized with COVID-19. Our work comprehensively mapped out inflammatory, humoral and adaptive immune responses following SARS-CoV-2 infection. Patients were recruited early following the lifting of strict public health measures in the Northern Territory, Australia, between November 2021 and May 2022. Australian First Nations peoples recovering from COVID-19 showed increased levels of MCP-1 and IL-8 cytokines, IgG-antibodies against Delta-RBD and memory SARS-CoV-2-specific T cell responses prior to hospital discharge in comparison with hospital admission, with resolution of hyperactivated HLA-DR

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralAustraliaHumansImmunityImmunoglobulin GIndigenous PeoplesAntibodies, ViralImmunoglobulin GAustralian First Nations peoplesCOVID-19RBD and N antibodiesSARS-CoV-2-specific T cells

Identifiers

PMID37725525
PMCPMC10872797

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.